Neoadjuvant Therapy in Pancreatic Cancer

REFERENCES

• Jemal A., et al. Cancer statistics, 2007. CA Cancer J. Clin. 2007; 57: 43–66
   PubMed Web of Science ®Google Scholar
• Sohn T. A., et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J. Gastrointest. Surg. 2000; 4(6)567–579
   PubMed Web of Science ®Google Scholar
• Evans D., Abbruzzesse J. L., Willett C. G. Cancer of the Pancreas. 6th ed., V. DeVita, S. Hellman, SA. Rosenberg. Lippincott Williams and Wilkins, Philadelphia 2001; 1126–1161, Cancer, Principles and Practice of Oncology
   Google Scholar
• Warshaw A. L., et al. Preoperative staging and assessment of resectability of pancreatic cancer. Arch. Surg. 1990; 125(2)230–233
   PubMed Web of Science ®Google Scholar
• Wolff R., et al. Initial Results of Preoperative Gemcitabine (GEM)-based Chemoradiation for Resectable Pancreatic Adenocarcinoma. Proc. Am. Soc. Clin. Oncol. 2002; 21: 130a
   Google Scholar
• Talamonti M. S., et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann. Surg. Oncol. 2006; 13(2)150–158
   PubMed Web of Science ®Google Scholar
• House M. G., et al. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J. Gastrointest. Surg. 2004; 8(3)280–288
   PubMed Web of Science ®Google Scholar
• Agarwal B., et al. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am. J. Gastroenterol. 2004; 99(7)1258–1266
   PubMed Web of Science ®Google Scholar
• Fernandez-del Castillo C., Rattner D. W., Warshaw A. L. Further experience with laparoscopy and peritoneal cytology in the staging of pancreatic cancer. Br. J. Surg. 1995; 82(8)1127–1129
   PubMed Web of Science ®Google Scholar
• Willett C. G., et al. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann. Surg. 1993; 217(2)144–148
   Web of Science ®Google Scholar
• Hoffman J. P., et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am. J. Surg. 1995; 169(1)71–77, discussion 77–78
   PubMed Web of Science ®Google Scholar
• Pisters P. W., et al. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann. Surg. 2001; 234(1)47–55
   PubMed Web of Science ®Google Scholar
• Yeo C. J., et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann. Surg. 1997; 226(3)248–257, discussion 257–260
   PubMed Web of Science ®Google Scholar
• Hoffman J. P., et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 1998; 16(1)317–323
   PubMed Web of Science ®Google Scholar
• Birkmeyer J. D., et al. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery. 1999; 125(3)250–256
   PubMed Web of Science ®Google Scholar
• Kalser M. H., Ellenberg S. S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg. 1985; 120(8)899–903
   Google Scholar
• Yeo C. J., et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann. Surg. 1997; 225(5)621–633, discussion 633–666
   PubMed Web of Science ®Google Scholar
• Demeure M. J., et al. Molecular metastases in stage I pancreatic cancer: improved survival with adjuvant chemoradiation. Surgery 1998; 124(4)663–669
   PubMed Web of Science ®Google Scholar
• Neoptolemos J. P., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004; 350(12)1200–1210
   PubMed Web of Science ®Google Scholar
• Koshy M. C., et al. A challenge to the therapeutic nihilism of ESPAC-1. Int. J. Radiat. Oncol. Biol. Phys. 2005; 61(4)965–966
   PubMed Web of Science ®Google Scholar
• Klinkenbijl J. H., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg. 1999; 230(6)776, 782, discussion 782–784
   PubMed Web of Science ®Google Scholar
• Breslin T. M., et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann. Surg. Oncol. 2001; 8(2)123–132
   PubMed Web of Science ®Google Scholar
• Evans D. B., et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch. Surg. 1992; 127(11)1335–1339
   PubMed Web of Science ®Google Scholar
• Pisters P. W., et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J. Clin. Oncol. 1998; 16(12)3843–3850
   PubMed Web of Science ®Google Scholar
• Micames C., et al. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA. vs. percutaneous FNA. Gastrointest. Endosc. 2003; 58(5)690–695
   PubMed Web of Science ®Google Scholar
• Weese J. L., et al. Increased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemoradiotherapy. Int. J. Pancreatol. 1990; 7(1–3)177, 185
   PubMedGoogle Scholar
• Spitz F. R., et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J. Clin. Oncol. 1997; 15(3)928–937
   PubMed Web of Science ®Google Scholar
• Griffin J. F., et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990; 66(1)56–61
   PubMed Web of Science ®Google Scholar
• Picozzi V. J., Traverso L. W. The Virginia Mason approach to localized pancreatic cancer. Surg. Oncol. Clin. N. Am. 2004; 13(4)663–74, ix
   PubMedGoogle Scholar
• Safran H., et al. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. J. Clin. Oncol. 1997; 15(3)901–907
   PubMed Web of Science ®Google Scholar
• Safran H., et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2001; 49(5)1275–129
   PubMed Web of Science ®Google Scholar
• Pisters P. W., et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J. Clin. Oncol. 2002; 20(10)2537–2544
   PubMed Web of Science ®Google Scholar
• Evans D. B. Preoperative chemoradiation for pancreatic cancer. Semin. Oncol. 2005; 32: S25–S29, (6 Suppl. 9)
   PubMed Web of Science ®Google Scholar
• Varadhachary G. R., et al. Borderline resectable pancreatic cancer. Curr. Treat. Options Gastroenterol. 2005; 8(5)377–384
   PubMedGoogle Scholar
• Tseng J. F., et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J. Gastrointest. Surg. 2004; 8(8)935–949, discussion 949–950
   PubMed Web of Science ®Google Scholar
• Ujiki M. B., et al. A novel peptide sansalvamide analogue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest. Biochem. Biophys. Res. Commun. 2006; 340(4)1224–1228
   PubMed Web of Science ®Google Scholar
• Jessup J. M., et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch. Surg. 1993; 128(5)559–564
   PubMed Web of Science ®Google Scholar
• Lawrence T. S., Eisbruch A., Shewach D. S. Gemcitabine-mediated radiosensitization. Semin. Oncol. 1997; 24: S7-24–S7-28, (2 Suppl. 7)
   Google Scholar
• Burris H. A., 3rd, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997; 15(6)2403–2413
   PubMed Web of Science ®Google Scholar
• Ammori J. B., et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J. Gastrointest. Surg. 2003; 7(6)766–772
   PubMed Web of Science ®Google Scholar
• Wolff R. A., et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin. Cancer Res. 2001; 7(8)2246–2253
   PubMed Web of Science ®Google Scholar
• McGinn C. J., et al. Phase Itrial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2001; 19(22)4202–428
   PubMed Web of Science ®Google Scholar
• Kim H. J., et al. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?. J. Gastrointest. Surg. 2002; 6(5)763–769
   PubMed Web of Science ®Google Scholar
• Sasson A. R., et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int. J. Gastrointest. Cancer. 2003; 34(2–3)121–128
   PubMedGoogle Scholar
• Pingpank J. F., et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J. Gastrointest. Surg. 2001; 5(2)121–130
   PubMed Web of Science ®Google Scholar
• Demols A., et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br. J. Cancer. 2006; 94(4)481–485
   PubMed Web of Science ®Google Scholar
• Louvet C., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 2005; 23(15)3509–3516
   PubMed Web of Science ®Google Scholar
• Rocha Lima C. M., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 2004; 22(18)3776–3783
   PubMed Web of Science ®Google Scholar
• Heinemann V., et al. A phase III trial comparing gemcitabine plus cisplatin vs gemcitabine alone in advanced pancreatic carcinoma. Proc. Am. Soc. Clin. Oncol. 2003, (Abstr. 1003)
   Google Scholar
• O'Reilly E., et al. A randomized phase III trial of DX-8951f (exatecan mesylate;DX) and gemcitabine (GEM) vs gemcitabine alone in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. 2004, (Abstr. 4006)
   Google Scholar
• Fogelman D. R., et al. The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX. Surg. Oncol. Clin. N. Am. 2004; 13(4)711–735, x
   PubMedGoogle Scholar
• Pipas J. M., et al. Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann. Surg. Oncol. 2005; 12(12)995–1004
   PubMed Web of Science ®Google Scholar
• Crane C. H., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J. Clin. Oncol. 2006; 24(7)1145–1151
   PubMed Web of Science ®Google Scholar
• Kindler H. L., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2005; 23(31)8033–8040
   PubMed Web of Science ®Google Scholar
• Czito B. G., et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J. Clin. Oncol. 2006; 24(4)656–662
   PubMed Web of Science ®Google Scholar
• Xiong H. Q., et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J. Clin. Oncol. 2004; 22(13)2610–2616
   PubMed Web of Science ®Google Scholar